Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Their pipeline comprises several studies, pre-clinical and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications.
The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.
Since its founding Galapagos has operated with a hybrid business model which has combined its internal discoveries with service activities. This model has worked quite well as it has now…
Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She…
Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its…
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Amgen has forged a solid position as one of the world’s largest independent biotechnology companies. With a market capitalisation of some USD 130 billion and 27 approved medicines, the US-based…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is…
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field –…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he…
Belgian healthcare performs strongly across most metrics and international comparisons, but – as elsewhere – there remains room for improvement in terms of integrating patient feedback and experience into the…
See our Cookie Privacy Policy Here
